Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. I: Formulation and in vitro characterization.
Positively charged mitoxantrone (MTO) was absorbed by negatively charged blank bovine serum albumin (BSA) and chitosan (CS) nanospheres to form MTO-BSA-NS and MTO-CS-NS, respectively. In addition to other conditions, values of pH of every step were optimized. On optimized conditions, MTO-BSA-NS of a mean size of 77 nm with an encapsulation yield (EY) of (98.86+/-1.43)% [drug loading rate (DL) (19.82+/-0.29)%] and MTO-CS-NS of a mean size of 75 nm with an EY of (97.57+/-1.00)% [DL (9.78+/-0.10)%] were obtained. After lyophilization and sterilization by (60)Co, the mean size increased about 10% but no significant change was observed in EY and DL. Tests for in vitro release in physiological saline or physiological saline containing 0.5% (w/v) ascorbic acid by a dialysis bag showed sustained release and little burst effect.
Lu
Bin
B
West China School of Pharmacy, Sichuan University, 610041, China. lubin@wcums.edu.cn
Xiong
Su-Bin
SB
Yang
Hong
H
Yin
Xiao-Dong
XD
Zhao
Ruo-Bing
RB
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002626:Chemistry, Pharmaceutical; D048271:Chitosan / Q000737:chemistry; D004355:Drug Stability; D005612:Freeze Drying; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007267:Injections; D008207:Lymphatic Metastasis / Q000517:prevention & control; D008942:Mitoxantrone / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use; D043942:Nanotubes; D012710:Serum Albumin, Bovine / Q000737:chemistry; D012995:Solubility; D013242:Sterilization; D013997:Time Factors
D000970:Antineoplastic Agents; D012710:Serum Albumin, Bovine; D048271:Chitosan; D008942:Mitoxantrone